CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data

Immunotherapy has greatly changed the status of cancer treatment, and many patients do not respond or develop acquired resistance. The related research is blocked by lacking of comprehensive resources for researchers to discovery and analysis signatures, then further exploring the mechanisms. Here,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2023-07, Vol.72 (7), p.2319-2330
Main Authors: Li, Feng, Dong, Kejing, Zhang, Chunlong, Wang, Jingwen, Tang, Yongjuan, Xue, Ke, Zheng, Xuan, Song, Kaiyue, Zhang, Xiaomeng, Li, Mengyue, Zhao, Rui, Zhong, Xiaoling, Xu, Yanjun, Zhang, Yunpeng, Li, Xia
Format: Article
Language:English
Subjects:
Cancer
Cancer immunotherapy
Cancer Research
Cell interactions
Humans
Immunology
Immunotherapy
Medicine
Medicine & Public Health
Neoplasms - genetics
Neoplasms - therapy
Oncology
Single-Cell Gene Expression Analysis
Survival analysis
Therapeutic targets
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy has greatly changed the status of cancer treatment, and many patients do not respond or develop acquired resistance. The related research is blocked by lacking of comprehensive resources for researchers to discovery and analysis signatures, then further exploring the mechanisms. Here, we first offered a benchmarking dataset of experimentally supported signatures of cancer immunotherapy by manually curated from published literature works and provided an overview. We then developed CiTSA ( http://bio-bigdata.hrbmu.edu.cn/CiTSA/ ) which stores 878 entries of experimentally supported associations between 412 signatures such as genes, cells, and immunotherapy across 30 cancer types. CiTSA also provides flexible online tools to identify and visualize molecular/cell feature and interaction, to perform function, correlation, and survival analysis, and to execute cell clustering, cluster activity, and cell–cell communication analysis based on single cell and bulk datasets of cancer immunotherapy. In summary, we provided an overview of experimentally supported cancer immunotherapy signatures and developed CiTSA which is a comprehensive and high-quality resource and is helpful for understanding the mechanism of cancer immunity and immunotherapy, developing novel therapeutic targets and promoting precision immunotherapy for cancer.
ISSN:0340-7004
1432-0851
1432-0851
DOI:10.1007/s00262-023-03414-6